MedTrace Logo

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

NCT04460456 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2022-06-30

No results posted yet for this study

Summary

A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies

Conditions

  • HER2 Positive Solid Tumors

Interventions

DRUG

SBT6050

Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2

DRUG

pembrolizumab

400 mg IV

DRUG

Cemiplimab

350 mg IV

Sponsors & Collaborators

  • Silverback Therapeutics

    lead INDUSTRY

Principal Investigators

  • Naomi Hunder, MD · Silverback Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-27
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04460456 on ClinicalTrials.gov